Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and ImmunityBio, Inc.

Navigating SG&A Expenses: A Tale of Two Biotech Giants

In the competitive landscape of biotechnology, effective cost management is crucial. Over the past decade, Gilead Sciences, Inc. and ImmunityBio, Inc. have demonstrated contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. Gilead Sciences, a leader in antiviral drugs, has seen its SG&A expenses grow by approximately 104% from 2014 to 2023, reflecting its expansive market reach and robust operational scale. In contrast, ImmunityBio, a smaller player focused on immunotherapy, has experienced a more volatile trajectory, with expenses peaking in 2015 and fluctuating thereafter. By 2023, ImmunityBio's SG&A expenses were about 2% of Gilead's, highlighting the stark difference in scale and operational strategy. This comparison underscores the diverse approaches within the biotech sector, where size and focus significantly influence financial strategies.